FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September 18, 2026 NDA submission for neladalkib in TKI ...
Operating plan details commitment and development schedule for the next four years of one of Central Europe's largest untapped natural resources Vancouver, British Columbia--(Newsfile Corp. - March 5, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results